[Clinical and hemodynamic effects of medium-term ketanserin treatment in 2 compared groups of obese and non-obese hypertensive patients].
We evaluated systemic and central hemodynamics in 10 lean hypertensives and in 10 obese hypertensives (WHO stage I-II) after 8 weeks treatment regimen with a serotoninergic antagonist such as ketanserin. At the beginning and at the end of the study, body weight, BMI, blood pressure and heart rate were measured and a first pass radionuclide angiocardiography was performed to determine cardiac output, cardiac index and ejection fraction of left ventricle. Total peripheral resistances were also calculated. In both hypertensive groups ketanserin significantly reduced diastolic (p less than 0.05) and mean (p less than 0.005) blood pressure. No significant change in systolic blood pressure, cardiac output, cardiac index and ejection fraction of left ventricle has been observed in lean and obese hypertensives. Total peripheral resistance values significantly (p less than 0.05) decreased in lean hypertensives; in obese hypertensives total peripheral resistance moderately reduced. Our results indicated that monotherapy with ketanserin is effective in treating mild to moderate hypertension both in lean and in obese hypertensives and did not interfere with left ventricular performance. At last the effectiveness of ketanserin treatment appears moderately higher in lean than in obese hypertensives.
Licata
G
G
Scaglione
R
R
Parrinello
G
G
Capuana
G
G
Mazzola
G
G
Lipari
R
R
Galantino
L
L
Castello
R
R
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006439:Hemodynamics; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007650:Ketanserin / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D009765:Obesity / Q000150:complications* / Q000503:physiopathology; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects
D007650:Ketanserin
Effetti clinici ed emodinamici del trattamento a medio termine con ketanserina in due gruppi di ipertesi obesi o non obesi posti a confronto.